Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk

Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers
European Respiratory Journal 2020; DOI: 10.1183/13993003.01919-2020
Puja Mehta
1Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK
2Department of Rheumatology, University College London Hospital (UCLH), London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Coziana Ciurtin
2Department of Rheumatology, University College London Hospital (UCLH), London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Coziana Ciurtin
Marie Scully
3Department of Haematology, University College London Hospital (UCLH), London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Levi
4Department of Medicine, University College London Hospitals (UCLH), London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel C. Chambers
1Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rachel C. Chambers
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

There is accumulating evidence that COVID-19 is a hypercoagulable state. Reports of thrombotic events and autopsy findings of pulmonary thrombotic microangiopathy [1] in patients with COVID-19 are rising. Bompard et al. recently reported a cohort study of 137 patients with COVID-19 pneumonia, in which retrospective review of computed tomography pulmonary angiography (CTPA) scans demonstrated a cumulative incidence of pulmonary emboli (PE) of 24% overall and 50% in intensive care [2]. Although it was initially thought that insidious venous thromboembolic events (VTE) were mainly confined to ventilated patients [3], we now understand thrombotic risk to be a wider problem in COVID-19. An overexuberant host inflammatory response, in selected patients with severe COVID-19, may contribute to the high mortality. We recently recommended screening for virally-driven hyperinflammation in COVID-19 and proposed that immunomodulation in this subgroup of patients, may improve outcomes [4]. There are several ongoing, randomised controlled trials evaluating the therapeutic potential of Janus Kinase inhibitors (JAKi) in severe COVID-19 (table 1). JAKi have a purported advantage over other immunomodulatory strategies in COVID-19, as they may exert dual anti-inflammatory (blockade of multiple, pro-inflammatory cytokines simultaneously) and anti-viral effects (impeding cellular viral endocytosis [5, 6]) and have convenient oral administration, with relatively short half-lives. JAKi may interrupt the signalling of several pro-inflammatory cytokines implicated in the pathogenesis of hyperinflammation, including interleukin (IL)-6, which has been the focus of several clinical trials in COVID-19. JAKi may also inhibit the entry of the SARS-CoV-2 virus into the AT2 alveolar epithelial cells; baricitinib (a JAK1/2 inhibitor), is a numb-associated kinase (NAK) inhibitor, with a particularly high affinity for AP2-associated protein kinase 1 (AAK1), a pivotal regulator of clathrin-mediated viral endocytosis [5]. We recommend vigilance to the potentially increased thrombotic risk associated with JAKi, given the hypercoagulability of COVID-19 and our recent thromboprophylaxis recommendations for all hospitalised patients with COVID-19 [7].

View this table:
  • View inline
  • View popup
TABLE 1

Summary of relevant licensed JAK inhibitors and thrombotic concerns

Several JAKi are licenced in rheumatoid arthritis (RA) and have Food and Drug Administration (FDA) black-box warning for venous and arterial thrombotic events (including deep venous thrombosis (DVT), PE and ischaemic stroke), resulting in dose restrictions (table 1). It is unclear whether the presumed prothrombotic risks are dependent on JAK selectivity, drug specificity, dose or treatment duration or are confounded by indication. Whilst there is evidence of dose-dependent increased thrombotic risk associated with tofacitinib (five-fold increased risk of PE compared with tumour necrosis factor therapy in RA) [8], a recent meta-analysis did not show an overall JAKi class pro-thrombotic signal [9]. Although a significantly increased incidence of thrombotic events (DVT and PE) was reported with bariticitinb in RA trials [10], this has not been observed in extension studies and recent trials in atopic dermatitis [11]. Post-marketing surveillance may delineate the true risk and whether this is disease-specific. It is unclear which JAK isoform (selectivity) confers impact on the efficacy or influences safety of these therapies for their licenced indications (e.g. rheumatoid arthritis) or in the new disease setting of COVID-19. It is important to note that at high doses, JAKi can become “pan-JAK” inhibitors and exhibit non-selectivity [12]

Discussion continues regarding whether JAKi have a causal role in thrombotic events, or whether this represents a higher background thrombotic risk [13]. Indeed VTE risk in RA (0.3–0.7/100 patient years) is greater compared with the general population (0.1–0.4/100 patient years) [13]. Intriguingly, ruxolitinib, unlike baricitinib, does not carry a VTE warning, despite both being selective JAK 1/2 inhibitors. Conversely there is a suggestion that ruxolitinib may lower the inherently raised thrombotic risk in myeloproliferative neoplasms [14]. Extrapolating this reassurance for ruxolitinib to COVID-19 is inappropriate as data for baricitinib and ruxolitinib is derived from different disease populations and their respective safety signals may be confounded by indication.

Clinical trials in COVID-19 using immunomodulation, including JAKi, intend to recruit patients with the most severe disease, and it is hypothesised that these patients are more hypercoagulable. We recommend risk mitigation strategies including consideration of exclusion of patients with high thrombotic risk, treatment with standard or intermediate-dose low molecular weight heparin prophlyaxis [7] during hospitalisation and consideration of extended-duration thromboprophylaxis after discharge from hospital, with monitoring for thromboses during the treatment and follow-up periods.

JAKi represent significant therapeutic advances, but are relatively new drugs with evolving safety profiles. Potential prothrombotic risk may be a class effect of JAKi, which is concerning given evidence of hypercoagulability with severe COVID-19. Cross-speciality communication is imperative when drug repurposing in the rapidly evolving pace of a pandemic.

Footnotes

  • Author contribution: PM drafted the manuscript. All authors contributed to discussions, revised and approved the manuscript.

  • Conflict of interest: Dr. Mehta reports and PM is an MRC-GSK EMINENT clinical training fellow with project funding outside the submitted work. PM receives co-funding by the NIHR University College London Hospitals Biomedical Research Centre (UCLH BRC).

  • Conflict of interest: Dr. Ciurtin has nothing to disclose.

  • Conflict of interest: Professor Scully has nothing to disclose.

  • Conflict of interest: Dr. Levi has nothing to disclose.

  • Conflict of interest: Dr. Chambers reports grants from UKRI MRC, grants from GlaxoSmithKline, grants from NIHR ULCH BRC, unrelated to this work.

  • Received May 21, 2020.
  • Accepted June 27, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Connors JM,
    2. Levy JH
    . COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020.
  2. ↵
    1. Bompard F,
    2. Monnier H,
    3. Saab I, et al.
    Pulmonary embolism in patients with Covid-19 pneumonia. Eur Respir J 2020; 190: 2001365. doi:10.1183/13993003.01365-2020
    OpenUrl
  3. ↵
    1. Criel M,
    2. Falter M,
    3. Jaeken J, et al.
    Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Eur Respir J 2020.
  4. ↵
    1. Mehta P,
    2. McAuley DF,
    3. Brown M, et al.
    COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020.
  5. ↵
    1. Stebbing J,
    2. Phelan A,
    3. Griffin I, et al.
    COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20: 400–402. doi:10.1016/S1473-3099(20)30132-8
    OpenUrlCrossRefPubMed
  6. ↵
    1. Richardson P,
    2. Griffin I,
    3. Tucker C, et al.
    Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30–e31. doi:10.1016/S0140-6736(20)30304-4
    OpenUrlCrossRefPubMed
  7. ↵
    1. Levi M,
    2. Thachil J,
    3. Iba T, et al.
    Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7: e438–e440 . doi:10.1016/S2352-3026(20)30145-9
    OpenUrl
  8. ↵
    1. EMA
    . Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis 2019. www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis. Date last accessed: May 16, 2020).
  9. ↵
    1. Xie W,
    2. Huang Y,
    3. Xiao S, et al.
    Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2019; 78: 1048–1054. doi:10.1136/annrheumdis-2018-214846
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Taylor PC,
    2. Weinblatt ME,
    3. Burmester GR, et al.
    Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71: 1042–1055. doi:10.1002/art.40841
    OpenUrl
  11. ↵
    1. Simpson EL,
    2. Lacour JP,
    3. Spelman L, et al.
    Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020.
  12. ↵
    1. Winthrop KL
    . The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13: 234–243. doi:10.1038/nrrheum.2017.23
    OpenUrlCrossRefPubMed
  13. ↵
    1. Scott IC,
    2. Hider SL,
    3. Scott DL
    . Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Saf 2018; 41: 645–653. doi:10.1007/s40264-018-0651-5
    OpenUrl
  14. ↵
    1. Samuelson BT,
    2. Vesely SK,
    3. Chai-Adisaksopha C, et al.
    The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis 2016; 27: 648–652. doi:10.1097/MBC.0000000000000446
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 61 Issue 5 Table of Contents
European Respiratory Journal: 61 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk
Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers
European Respiratory Journal Jan 2020, 2001919; DOI: 10.1183/13993003.01919-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk
Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers
European Respiratory Journal Jan 2020, 2001919; DOI: 10.1183/13993003.01919-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Latent COPD: a proposed new term in the disease nomenclature
  • Anti-anaerobic antibiotics: indication is key
  • Reply: Anti-anaerobic antibiotics: indication is key
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society